Ceregene, the San Diego-based gene therapy company, said today it has raised $11.5 million in a Series D venture round. Hamilton BioVentures and Alta Partners led the deal, which included MPM Capital and Investor Growth Capital. Ceregene said plans to use the money to complete a Phase 2b clinical trial of its experimental treatment CERE-120 for Parkinson’s disease. Back in December 2008, Ceregene said a mid-stage trial of 58 patients failed to show a statistically significant advantage when compared to a placebo. For more on Ceregene and its strategy against Parkinson’s disease, check out this profile we ran back in October 2008.